Mikafungin Teva (Micafungin Sodium)

Micafungin Sodium, the active ingredient in Mikafungin Teva, is an echinocandin presented as an injection solution for intravenous use. It is indicated for the treatment of serious systemic fungal infections, including invasive candidiasis, esophageal candidiasis, Candida peritonitis, and febrile neutropenia associated with fungal infection in immunocompromised patients.

GNH USA supplies Mikafungin Teva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres and pharmacies worldwide, providing reliable cold‑chain logistics and regulatory support to meet global distribution.

Micafungin Sodium is used to treat fungal infections by inhibiting cell‑wall synthesis.

Invasive candidiasis: effective for bloodstream and deep‑tissue Candida infections, reducing mortality in high‑risk patients. Esophageal candidiasis: clears mucosal Candida lesions and relieves dysphagia. Candida peritonitis: resolves intra‑abdominal Candida infection in postoperative or peritoneal dialysis patients. Febrile neutropenia (fungal): provides rapid antifungal coverage in neutropenic patients with suspected invasive fungal disease.

Common Side Effects: - Infusion‑related reactions such as flushing or chills. - Mild gastrointestinal symptoms including nausea or abdominal discomfort. - Transient elevation of liver enzymes (ALT, AST). - Headache or dizziness. - Rash or mild pruritus. Serious or Rare Side Effects: - Severe hepatotoxicity or hepatic failure. - Anaphylactic or severe allergic reactions. - Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Acute renal impairment. - Cardiac arrhythmias or hypotension.

Before initiating therapy, consider the following precautions: - Monitor liver function tests: baseline and periodic assessment recommended. - Assess renal function: dose adjustment may be needed in severe impairment. - Evaluate for hypersensitivity: discontinue if signs of severe allergic reaction appear. - Use caution in patients with pre‑existing hepatic disease. - Avoid concomitant use with strong CYP3A4 inducers that may reduce exposure. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Micafungin Sodium may interact with several drug classes.

Major Interactions (Avoid): - Co‑administration with strong CYP3A4 inducers (e.g., rifampin) can markedly reduce micafungin exposure. - Concurrent use with other echinocandins may increase risk of additive toxicity.

Moderate Interactions (Monitor Closely): - Combination with azole antifungals (e.g., fluconazole) may require liver enzyme monitoring. - Use with immunosuppressants such as tacrolimus or cyclosporine may necessitate dose adjustments. - Concurrent hepatotoxic agents (e.g., acetaminophen high doses) should be monitored for liver safety.